Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
life sciences
national blog main
new york blog main
5
×
boston top stories
cancer
clinical trials
fda
ipo
national top stories
new york top stories
san diego blog main
san francisco blog main
biogen
boston
boulder/denver blog main
boulder/denver top stories
deerfield management
detroit blog main
detroit top stories
drug discovery
europe blog main
europe top stories
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
san francisco top stories
sanofi
seattle blog main
seattle top stories
startups
takeda pharmaceutical
texas blog main
What
ipo
5
×
medicines
5
×
bio
covid
experimental
new
roundup
acquisitions
activity
ago
announced
approvals
based
begin
biogen
biosciences
biotechs
bio’s
brings
bubbles
cells
ceo
clamped
class
clinical
codiak
collabs
company’s
considering
course
daniel
data
deal
delays
developing
development
discover
diseases
drug
dyne
Language
unset
Current search:
medicines
×
ipo
×
" new york blog main "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline